These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32078585)

  • 1. Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopenia.
    Pan C; Jaiswal Agrawal N; Zulia Y; Singh S; Sha K; Mohler JL; Eng KH; Chakkalakal JV; Krolewski JJ; Nastiuk KL
    JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32078585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGFβ Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice.
    Pan C; Singh S; Sahasrabudhe DM; Chakkalakal JV; Krolewski JJ; Nastiuk KL
    Endocrinology; 2016 Nov; 157(11):4461-4472. PubMed ID: 27611336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
    Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
    Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration.
    Egerman MA; Cadena SM; Gilbert JA; Meyer A; Nelson HN; Swalley SE; Mallozzi C; Jacobi C; Jennings LL; Clay I; Laurent G; Ma S; Brachat S; Lach-Trifilieff E; Shavlakadze T; Trendelenburg AU; Brack AS; Glass DJ
    Cell Metab; 2015 Jul; 22(1):164-74. PubMed ID: 26001423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DA-Raf and the MEK inhibitor trametinib reverse skeletal myocyte differentiation inhibition or muscle atrophy caused by myostatin and GDF11 through the non-Smad Ras-ERK pathway.
    Masuzawa R; Takahashi K; Takano K; Nishino I; Sakai T; Endo T
    J Biochem; 2022 Jan; 171(1):109-122. PubMed ID: 34676394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.
    Couderc AL; Villani P; Berbis J; Nouguerède E; Rey D; Rossi D; Lechevallier É; Badinand D; Bastide C; Karsenty G; Boissier R; Amichi K; Muracciole X
    BMC Cancer; 2022 Jan; 22(1):78. PubMed ID: 35042460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer.
    Couderc AL; Muracciole X; Nouguerede E; Rey D; Schneider S; Champsaur P; Lechevallier E; Lalys L; Villani P
    J Nutr Health Aging; 2020; 24(2):205-209. PubMed ID: 32003412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GDF11 does not improve the palmitate induced insulin resistance in C2C12.
    Jing YY; Li D; Wu F; Gong LL; Li R
    Eur Rev Med Pharmacol Sci; 2017 Apr; 21(8):1795-1802. PubMed ID: 28485800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supraphysiologic Administration of GDF11 Induces Cachexia in Part by Upregulating GDF15.
    Jones JE; Cadena SM; Gong C; Wang X; Chen Z; Wang SX; Vickers C; Chen H; Lach-Trifilieff E; Hadcock JR; Glass DJ
    Cell Rep; 2018 Feb; 22(6):1522-1530. PubMed ID: 29425507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
    Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
    Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of concurrent training order on body composition and serum concentrations of follistatin, myostatin and GDF11 in sarcopenic elderly men.
    Bagheri R; Moghadam BH; Church DD; Tinsley GM; Eskandari M; Moghadam BH; Motevalli MS; Baker JS; Robergs RA; Wong A
    Exp Gerontol; 2020 May; 133():110869. PubMed ID: 32035222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
    Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
    J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone.
    Suh J; Kim NK; Lee SH; Eom JH; Lee Y; Park JC; Woo KM; Baek JH; Kim JE; Ryoo HM; Lee SJ; Lee YS
    Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4910-4920. PubMed ID: 32071240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
    Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal Systemic AAV-Mediated Gene Delivery of GDF11 Inhibits Skeletal Muscle Growth.
    Jin Q; Qiao C; Li J; Li J; Xiao X
    Mol Ther; 2018 Apr; 26(4):1109-1117. PubMed ID: 29503194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of Circulating Growth and Differentiation Factors 8 and 11 and Their Antagonists as Measured Using Liquid Chromatography-Tandem Mass Spectrometry With Age and Skeletal Muscle Strength in Healthy Adults.
    Semba RD; Zhang P; Zhu M; Fabbri E; Gonzalez-Freire M; Carlson OD; Moaddel R; Tanaka T; Egan JM; Ferrucci L
    J Gerontol A Biol Sci Med Sci; 2019 Jan; 74(1):129-136. PubMed ID: 30380014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
    Mitsuzuka K; Arai Y
    Int J Urol; 2018 Jan; 25(1):45-53. PubMed ID: 29052905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of androgen deprivation therapy on elderly men with high-risk prostate cancer: PROSARC observational study.
    Legido-Gómez Ó; Rico-Marco S; Lorenzo-Sánchez MV; Navarro-Jiménez S; Tárraga-Honrubia MA; Martínez-Ruiz J; Giménez-Bachs JM; Donate-Moreno MJ; Díaz de Mera-Sánchez-Migallón I; Segura-Martín M; Alcantud-Córcoles R; Abizanda-Soler P; Salinas-Sánchez AS
    Actas Urol Esp (Engl Ed); 2024 May; 48(4):304-310. PubMed ID: 38373481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiological levels of GDF11 activate Smad2/Smad3 signaling and induce muscle atrophy in human iPSC-derived myocytes.
    Honda M; Makino T; Zhao X; Matsuto M; Sakurai H; Takahashi Y; Shimizu M; Sato R; Yamauchi Y
    Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1402-C1409. PubMed ID: 36094432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.